About Nektar
Nektar is a publicly listed company based in San Francisco (United States) founded in 1990. Therapeutics for multiple diseases are developed using PEGylation platforms. The company has 61 employees. Nektar has completed 1 acquisition, including Aerogen. Its website nektar.com draws about 20 thousand monthly visits. Its Indian entity Nektar Therapeutics (India) Private Limited reported revenue of ₹3.39 Cr. Nektar offers products and services including REZPEG, PEG-CSF1, and TNFR-2. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 1990 and based in San Francisco, United States, the company operates in the biotechnology sector. Drug candidates are developed through PEGylation and polymer conjugate technologies to address cancer, pain, anti-infectives, anti-viral, and immunological conditions. The pipeline features NKTR-358 for autoimmune diseases, Bempegaldesleukin for viral indications, and various oncology programs.
- Headquarters San Francisco, United States
- Employees 61
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website nektar.com
- Social LinkedIn X
- Legal Name Nektar Therapeutics
- Indian entity revenue₹3.39 Cr
FY 2025 · -8% YoY
- Indian entity net profit₹1.77 Cr
FY 2025 · 52% margin
- Indian entity EBITDA₹2.53 Cr
FY 2025 · 75% margin
- Latest Funding Round$30M (USD), Post-IPO
Mar 2024
- InvestorsAstrazeneca
& 2 more
- Employee Count61
- Investments & Acquisitions
Associated legal entities of Nektar
Nektar operates through Nektar Therapeutics (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Nektar Therapeutics (India) Private Limited CIN U24239TG2005FTC046253 | Active | 16 May 2005 | Hyderabad, Telangana | ₹3.4 Cr | 3 | 4 | View details |
Products & Services of Nektar
Nektar offers a comprehensive portfolio of products and services, including REZPEG, PEG-CSF1, and TNFR-2.
Targets immune pathways for autoimmune disorder treatment.
Modulates immune responses for inflammatory conditions.
Advances treatments for chronic inflammatory diseases.
Funding Insights of Nektar
- Total Rounds 5
- Last Round Post-IPO — $30M
- Investors Count 3
All 5 funding rounds of Nektar with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $30M | Post-IPO | – | – | – |
| Mar 2019 | Post-IPO | – | – | ||
| Apr 2018 | $850M | Post-IPO | – | – | – |
| Aug 2013 | $25M | Post-IPO | – | – | |
| Jun 2011 | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in Nektar
Nektar has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, BB Biotech and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in Asia and Europe | 1993 | bbbiotech.ch | Schaffhausen, Switzerland | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for Nektar
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Nektar Therapeutics (India) Private Limited (Nektar)
Nektar Therapeutics (India) Private Limited is the primary company behind Nektar. The board of Nektar Therapeutics (India) Private Limited currently have 3 directors; the longest-serving is Mark Andrew Wilson, appointed in 2019. 20 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mark Andrew Wilson DIN 08391710 | Director | 19 Mar 2019 | 7 yrs 7 mo | Nektar Therapeutics (India) Private Limited |
| Uday Chandra Yemmanuru DIN 01581364 | Director | 25 Mar 2024 | 2 yrs 7 mo | Nektar Therapeutics (India) Private Limited |
| Robert Michael Bacci DIN 10671198 | Director | 18 Jun 2024 | 2 yrs 4 mo | Nektar Therapeutics (India) Private Limited |
People of Nektar
110 people are tracked at Nektar (53 in leadership, 6 in board & advisors, 51 in team); the tracked headcount is 61.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership | |
Jonathan Zalevsky | Chief Scientific Officer | Leadership |
Michelle Gossage | Associate Director Clinical Training | Leadership |
Damon Hamel | Senior Director Of Research Biology | Leadership |
Karyn Cassello | Executive Director, Clinical Systems & Compliance | Leadership |
Connie Brown | Director, Clinical Supplies Management | Leadership |
Sandra Gardiner | CFO | Leadership |
Howard Robin | President & CEO | Leadership |
Jennifer Ruddock | Senior Vice President & Chief Business Officer | Leadership |
Saul Kivimäe | Executive Director Head Of Pharmacology And Early Discovery | Leadership |
Tom Tarara | Director | Leadership |
Christie Fanton | Vice President, Translational Medicine & Clinical Pharmacology | Leadership |
Mario Marcondes M.D. | Vice President Head Of Clinical Development | Leadership |
Takahiro Miyazaki | Senior Vice President, Head Of Research | Leadership |
Dave Worlund | Associate Director Of Cost Accounting | Leadership |
Jason Barnard | Chief Accounting Officer | Leadership |
Lindsey Kadchhud | Senior Director Human Resources | Leadership |
Khushal Maru | Associate Director – Accounts | Leadership |
Amy Allen | Executive Director, Finance & Outsourcing | Leadership |
Marie Antoinette Chavez | Vice President And Associate General Counsel | Leadership |
90 more people are available in the full profile.
Complete people profiles for Nektar
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Nektar
Nektar is a publicly listed company on the NASDAQ with ticker symbol NKTR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 May 1994
- Listed onNASDAQ: NKTR
- Listed entityNektar Therapeutics
- Exchange sectorHealth technology
- ISINUS6402683063
- Share price$37.92 (-4.82% on the day) · 2026-10-13
- Market capitalisation$1.29B
- EPS (diluted, trailing year)$-6.70
- Volume (last session)2,044,401
Financials of Nektar
Figures of Nektar Therapeutics (India) Private Limited, the primary company behind Nektar, for FY 2025. Revenue was ₹3.39 Cr (-8% year on year). Net profit was ₹1.77 Cr (52% margin). EBITDA was ₹2.53 Cr (75% margin). Revenue has grown at a compounded annual rate of -65% over three years and -46% over five years.
- ₹3.39 CrRevenue · FY 2025 · -8% YoY
- ₹1.77 CrNet profit · 52% margin
- ₹2.53 CrEBITDA · 75% margin
- ₹29.39 CrPaid-up capital
- 3Employees (provident fund records)
- -65%Revenue CAGR, 3 years
- -46%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $55.2M | -$164.1M | -$133.4M |
| 2024 | $98.4M | -$119.0M | -$128.7M |
| 2023 | $90.1M | -$276.1M | -$129.6M |
| 2022 | $92.1M | -$368.2M | -$228.0M |
| 2021 | $101.9M | -$523.8M | -$433.1M |
Balance sheet, profit and loss, cash flow and ratios of Nektar Therapeutics (India) Private Limited are on its company page.
Detailed financial statements for Nektar
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nektar
Nektar has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Aerogen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Vibrating mesh nebulizers are manufactured for aerosol drug delivery. | aerogen.com | Galway, Ireland | 1997 | Aug 2005 | $32M |
Complete acquisition details for Nektar
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Nektar
5 dated milestones of Nektar across 34 years, from founding to its latest funding, stage changes and deals.
- Founded Nektar is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Aerogen.
- Funding First funding round.
- Funding Latest funding round, Post-IPO, of $30.0M.
Competitors of Nektar
Nektar has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Nektar
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nektar
The website of Nektar (nektar.com) receives about 19.6K visits a month and ranks #959,308 among all websites worldwide, #1,167 in Biotechnology and Pharmaceuticals.
- Monthly visits19.6K
▼ 3.6% vs previous month
- Unique visitors9.4K
per month
- Global rank#959,308
among all websites
- Category rank#1,167
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit4.4
- Average visit1 min 43 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with Nektar. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| astellasgenetherapies.com | 100% | 1K | View details | ||
| corvuspharma.com | 100% | 13.6K | #3,366,661 | View details | |
| amgen.com | 98% | 495.4K | #116,434 | View details | |
| mbcbiolabs.com | 98% | #2,013,343 | View details | ||
| nurixtx.com | 98% | 11.5K | #2,207,206 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Nektar
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Nektar (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nektar
Complete news archive for Nektar
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nektar
Nektar was founded in 1990 and raised its 1st funding round 21 years after it was founded.
Nektar is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Nektar has 61 employees.
The primary company behind Nektar, Nektar Therapeutics (India) Private Limited, reported revenue of ₹3.39 Cr for FY 2025, down 8% year on year.
Founded in 1990 and based in San Francisco, United States, the company operates in the biotechnology sector. Drug candidates are developed through PEGylation and polymer conjugate technologies to address cancer, pain, anti-infectives, anti-viral, and immunological conditions. The pipeline features NKTR-358 for autoimmune diseases, Bempegaldesleukin for viral indications, and various oncology programs.
Nektar's top competitors include C4 Therapeutics, Erasca and MiRagen.
Nektar offers REZPEG, PEG-CSF1, and TNFR-2.
Yes, Nektar is publicly traded on NASDAQ under the ticker symbol NKTR.
Nektar has made 1 acquisition, including Aerogen.
Nektar has 3 investors. Key investors include Astrazeneca, BB Biotech, and NEA.
Nektar operates through Nektar Therapeutics (India) Private Limited.
The legal entities of Nektar currently have 4 directors, including Mark Andrew Wilson, Phaneendra Modali, Uday Chandra Yemmanuru and others.